Narrower radiation after brain tumor surgery aims to spare healthy tissue

NCT ID NCT07368283

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a smaller radiation target area after glioblastoma surgery can control the tumor while causing fewer side effects. About 79 patients will receive limited-field radiotherapy plus standard chemotherapy. The main goals are to see how many patients are alive without tumor growth at 6 months and to measure serious brain damage from radiation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
limited-field radiotherapy plus temozolomide chemotherapy
What this could lead to
If successful, this approach could reduce long-term brain side effects from radiation while still controlling the tumor.
What could go wrong
This is a small, early-phase study with no control group, so results may not be definitive. The limited radiation field might also miss some cancer cells, increasing the risk of recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.